Table 1.
The characteristics of all included eligible studies about NK cells.
| Author | Year | Country | Sample size | Male/Female | Measurement | Marker | Treatment | Source | Tumor stage | VS | Numberof VS | Divide | Outcome | Follow-up times | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhuang et al. (34) | 2019 | China | 78 | 64/14 | NA | CD56 | mixed+SBRT | Peripheral blood | NA | High/Low | NA | cutoff value | OS;PFS | median:32 (4.1-80) month |
7 |
| Hu et al. (25) | 2021 | China | 182 | NA | Immuno histochemistry |
CD57 | resection | Intratumor | I-IV | High/Low | NA | NA | OS;TTR | until 30/06/2016 | 7 |
| Lin et al. (35) | 2013 | China | 132 | NA | Immuno histochemistry |
CD56 | resection | Intratumor | I-III | High/Low | NA | cutoff value | OS;DFS | total:72 month | 8 |
| Wu et al. (20) | 2013 | China | 256 | 115/15 | Immuno histochemistry |
CD57 | resection/RFA | Intratumor | I-IV | High/Low | 126/130 | median | OS;DFS | NA | 9 |
| Tao et al. (26) | 2020 | China | 258 | NA | Immuno histochemistry |
CD56 | resection | Intratumor | I-III | High/Low | 129/129 | median | OS;TTR | NA | 9 |
| Chew et al. (22) | 2012 | China | 36 | NA | Immuno histochemistry |
CD56 | resection | Intratumor | I-IV | High/Low | NA | median | OS | median:3.94 (0.9-5.5) year |
6 |
| Zhao et al. (21) | 2014 | China | 163 | 131/32 | Immuno histochemistry |
CD57 | resection | Intratumor | NA | High/Low | 82/81 | median | OS | total:>60 month | 9 |
| Gao et al. (36) | 2012 | China | 206 | NA | Immuno histochemistry |
CD57 | liver transplantation | Intratumor | I-III | High/Low | NA | median | CSS;RFS | median:48.1 (3.4- 111.9) month |
8 |
| Cariani et al. (23) | 2016 | Italy | 70 | 41/29 | Flow cytometry | NK cells | resection/RFA | Peripheral blood | NA | High/Low | NA | median | OS;TTR | median OS:64 month; median TTR:16.5 month |
7 |
| Pan et al. (37) | 2014 | China | 121 | NA | Flow cytometry | CD56 | resection+CIK | Peripheral blood | NA | High/Low | 60/61 | median | OS | until 31/12/2012 | 9 |
| Liu et al. (38) | 2021 | China | 100 | NA | Immuno histochemistry |
CD56 | resection | Intratumor | NA | Positive/ Negative |
31/68 | score | RFS | until:20/06/2020 | 6 |
| Pan et al. (27) | 2020 | China | 48 | 39/9 | Flow cytometry | CD56 | resection+CIK | Peripheral blood | NA | High/Low | 24/24 | median | OS;RFS | total:>60 month | 7 |
| Che et al. (39) | 2014 | China | 61 | NA | Flow cytometry | NK cells | resection | Peripheral blood | NA | High/Low | 33/28 | median | OS;PFS | total:36 month | 6 |
SBRT, Stereotactic body radiation therapy; RFA, Radiofrequency ablation; CIK, Cytokine-induced killer; Mixed, TACE or RFA or PEI or surgery or no treatment; TAE, Transcatheter arterial embolization; NK, Natural killer; OS, Overall survival; DFS, Disease-free survival; RFS, Recurrence-free survival; TTR, Time-to recurrence; PFS, Progression-free survival; CSS, Cancer-specific survival.
NA, Not available.